The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC
Primary Objective: To Evaluate the Effect of GB004 Compared to Placebo on Clinical Remission
The purpose of the LATTICE-UC is to evaluate how well the oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active ulcerative colitis.
The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.
To assess the change in symptoms and overall safety of TD-1473, which is an investigational product, in moderately-to-severely active Crohn's disease.
To assess the change in symptoms and overall safety of TD-1473, which is an investigational product, in moderately-to-severely active UC.
- We are conducting interviews with adults who have been clinically diagnosed with Ulcerative Colitis (UC) that is currently moderately-to-severely active based on clinician assessment.
- The focus of the interviews will be to gain a better understanding of the participant's experience living with ulcerative colitis, including what symptoms are most important to them and how these symptoms may impact their day-to-day life.
- To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
- To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD
- To evaluate the efficacy of PF-06480605 in induction of clinical remission at Week 14 in participants with moderate to severe active UC.
- To evaluate the safety and tolerability of PF-06480605 during the chronic therapy period (from Week 14 to the End of Study Visit) in participants with moderate to severe active UC during the chronic therapy period.
The primary objective of this study is to evaluate whether investigational cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).